🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

"If the lesson you learned is not to take risks, biotech’s a tough business to succeed in. We want to learn the lessons around operating well, and we want to learn the lessons around taking clean shots." Matt Gline BioPharma Dive #biotech #PharmaNews biopharmadive.com/news/matt-glin…

The dual price point for biosimilars (Humira most recent) is a rare behind-the-scenes look at some of the weird stuff that happens in pricing negotiations between pharma companies and PBMs/payers in America

Don't miss CEO Matt Gline on Tuesday Feb 7th at 4pm ET at the #BIOCEO23 panel entitled "Timing the Next Wave of Strategic M&A" alongside Bayer | Pharmaceuticals J.P. Morgan Anna Kazanchyan MD, moderated by Michelle F. Davis. Watch this space for updates!

I could quibble with the word “scraps” in the title, but hard to argue with David Wainer when he suggests the payoff for patients and investors could be large! Thanks for the feature David and The Wall Street Journal wsj.com/articles/colle…

Thanks for having me Rahul Chaturvedi!

As we reflect on the many contributions that women have made in #biotech, including Rosalind Frank who played a fundamental role in deciphering the structure of DNA, we want to say thank you to all of the women at Roivant Sciences. #InternationalWomensDay #womenshistorymonth2023

Incyte’s Opzelura cream may be looking at a new competitive rival in the lucrative atopic dermatitis field. loom.ly/9ULV12Y

We are excited to announce a new ADAR1 focused drug discovery collaboration with leading pharma company Boehringer Ingelheim. Boehringer Ingelheim Roivant Sciences globenewswire.com/news-release/2…

"Many of our best people at Roivant are deeply, innately curious, and I think it’s important to nurture that curiosity – about the science, about the business, about why things are the way they are and whether there’s a better way.” Matt Gline #biotech #leader bit.ly/420u42l

Read why our CEO Matt Gline says: "I came to realize that at least some people – and I put myself in this category – really thrive when our back is to the wall and there’s no way out but through.” #leadership #biotech #partnership #pharma invivo.pharmaintelligence.informa.com/IV147710/Finge…

“We’re incredibly honored to receive this recognition. Roivant has always prided itself not only on our innovative business model but also on our commitment to fostering a culture that challenges convention and drives transformative change in the #biopharma industry,”Matt Gline

People like to talk about the importance of "vision," but ultimately running a startup is like doing science: you have to follow the truth wherever it leads. Vision is only valuable insofar as it predicts where you'll find truth.

The Roivant team had an amazing day at EAST NEW YORK FARMS! for our annual NYC Roivant Day of Service! Thanks to all those who participated! #CommunityService #BuildingCommunity #Gardening #NYC

Thanks for having me over Andrew Dunn! It was a lot of fun!

No shame in coming behind Dave Ricks. Adam Feuerstein ✡️ thanks for including us!

Great chatting with you Michelle F. Davis! Thanks for having us at #BIO24, Biotechnology Innovation Organization!

𝐓𝐨𝐦𝐨𝐫𝐫𝐨𝐰: Tune in tomorrow for a new episode of Off-Target Effects with Matt Gline. Matt interviews Avoro Capital's Behzad Aghazadeh.

This was a fun conversation! Thanks Behzad, Brad Loncar and @BiotechTVHQ

This was a fun one, Adam Feuerstein ✡️!

Congrats Brad Loncar!